Published in J Biomed Sci on December 05, 2007
Functions of autophagy in normal and diseased liver. Autophagy (2013) 1.81
Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol (2009) 1.56
Role of MicroRNAs in Hepatocellular Carcinoma. Hepat Mon (2014) 1.17
Huo-Luo-Xiao-Ling Dan modulates antigen-directed immune response in adjuvant-induced inflammation. J Ethnopharmacol (2009) 1.01
Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high risk for hepatocellular carcinoma. Carcinogenesis (2010) 0.97
Molecular epidemiology of hepatitis B virus. Korean J Intern Med (2011) 0.89
Novel method for genotyping hepatitis B virus on the basis of TaqMan real-time PCR. J Clin Microbiol (2010) 0.88
Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med (2015) 0.86
Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein Cell (2012) 0.84
Etiology and Viral Genotype in Patients with End-Stage Liver Diseases admitted to a Hepatology Unit in Colombia. Hepat Res Treat (2011) 0.84
Risk stratification of HBV infection in Asia-Pacific region. Clin Mol Hepatol (2014) 0.84
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
Predominance of precore mutations and clinical significance of basal core promoter mutations in chronic hepatitis B virus infection in Indonesia. Biomed Rep (2013) 0.83
Hepatitis B virus infection: An insight into infection outcomes and recent treatment options. Virusdisease (2015) 0.80
The Correlation Between Interferon Lambda 3 Gene Polymorphisms and Susceptibility to Hepatitis B Virus Infection. Hepat Mon (2016) 0.79
Clinical utility of complex mutations in the core promoter and proximal precore regions of the hepatitis B virus genome. World J Hepatol (2015) 0.78
Aligning to the sample-specific reference sequence to optimize the accuracy of next-generation sequencing analysis for hepatitis B virus. Hepatol Int (2015) 0.77
Support of the infectivity of hepatitis delta virus particles by the envelope proteins of different genotypes of hepatitis B virus. J Virol (2014) 0.77
Genetic analysis of complement component 9 (C9) polymorphisms with clearance of hepatitis B virus infection. Dig Dis Sci (2011) 0.76
Retrospective study of the prevalence and clinical significance of hepatitis B virus precore and basal core promoter variants. Can J Gastroenterol Hepatol (2015) 0.75
Characteristics of an outpatient chronic hepatitis B virus infection cohort. Einstein (Sao Paulo) (2015) 0.75
Association of TNF-α Gene Polymorphisms with Production of Protein and Susceptibility to Chronic Hepatitis B Infection in the South East Iranian Population. Hepat Mon (2016) 0.75
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis (2008) 3.01
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med (2013) 2.84
Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol (2005) 2.58
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int (2005) 2.46
High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology (2012) 2.36
The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol (2011) 2.02
Reduced toll-like receptor 9 expression on peripheral CD14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy. Antivir Ther (2014) 1.99
High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology (2006) 1.87
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol (2011) 1.86
Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis (2006) 1.84
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology (2008) 1.81
Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. J Gastroenterol (2002) 1.76
Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology (2007) 1.75
Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol (2007) 1.71
Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology (2007) 1.70
Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2009) 1.66
Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. J Gastroenterol Hepatol (2013) 1.64
Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol (2004) 1.55
Esophageal varices: noninvasive diagnosis with duplex Doppler US in patients with compensated cirrhosis. Radiology (2008) 1.54
Higher cut-off index value of immunoglobulin M antibody to hepatitis B core antigen in Taiwanese patients with hepatitis B. J Gastroenterol Hepatol (2006) 1.50
Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis (2011) 1.49
Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology (2011) 1.49
Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg (2005) 1.48
Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. J Clin Virol (2013) 1.45
Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology (2012) 1.39
Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int (2007) 1.38
Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology (2004) 1.36
Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis (2006) 1.29
Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol (2009) 1.29
Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proc Natl Acad Sci U S A (2013) 1.28
Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Semin Liver Dis (2013) 1.28
Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis (2007) 1.25
Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A (2011) 1.19
Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology (2012) 1.18
IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations. J Gen Virol (2011) 1.16
Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chin Med Assoc (2007) 1.12
Hepatitis B viral genotypes and lamivudine resistance. J Hepatol (2002) 1.12
Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut (2012) 1.10
Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther (2010) 1.10
Therapeutic implications of hepatitis B virus genotypes. Liver Int (2005) 1.10
Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol (2006) 1.08
Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci (2010) 1.07
Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study. Hepatology (2014) 1.05
Asymptomatic chronic hepatitis B virus infection does not increase the risk of diabetes mellitus: a ten-year observation. J Gastroenterol Hepatol (2010) 1.03
Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int (2005) 1.03
High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int (2007) 1.03
Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol (2011) 1.02
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Antivir Ther (2011) 1.02
Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol (2011) 1.01
Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study. Clin Infect Dis (2013) 1.01
Genotypic dominance and novel recombinations in HBV genotype B and C co-infected intravenous drug users. J Med Virol (2004) 1.00
Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect (2011) 1.00
Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol (2007) 1.00
Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology (2003) 0.99
Noninvasive diagnosis of hepatic fibrosis in patients with chronic hepatitis C by splenic Doppler impedance index. Clin Gastroenterol Hepatol (2007) 0.99
High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. J Med Virol (2004) 0.99
Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol (2012) 0.99
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy. Antivir Ther (2011) 0.99
Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol (2013) 0.98
Evolution of Hepatitis B virus in an acute hepatitis B patient co-infected with genotypes B and C. J Gen Virol (2006) 0.97
Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. Hepatology (2013) 0.97
Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol (2005) 0.96
Hepatitis B virus infection and metabolic syndrome: fact or fiction? J Gastroenterol Hepatol (2015) 0.96
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology (2013) 0.96
Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int (2006) 0.95
TT virus infection in healthy children, children after blood transfusion, and children with non-A to E hepatitis or other liver diseases in Taiwan. J Med Virol (2003) 0.94
Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther (2009) 0.94
Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS One (2013) 0.93
Optimal management of hepatocellular carcinoma: challenges and opportunities. J Gastroenterol Hepatol (2010) 0.93
Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol (2009) 0.93
HBV genotype and clinical outcome of chronic hepatitis B: facts and puzzles. Gastroenterology (2008) 0.92
Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol (2006) 0.91
Hepatitis B virus basal core promoter mutation and DNA load correlate with expression of hepatitis B core antigen in patients with chronic hepatitis B. J Infect Dis (2009) 0.91
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis (2010) 0.90
Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis. J Med Virol (2004) 0.90
Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B. Liver Int (2006) 0.90
Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. Hepatology (2002) 0.90
Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. Antivir Ther (2009) 0.90
Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol (2011) 0.90
Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. Clin Gastroenterol Hepatol (2004) 0.90
A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. Liver Int (2008) 0.89
Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther (2008) 0.89
A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. Gastroenterology (2003) 0.89
Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: Correlation with viral characteristics. J Gastroenterol Hepatol (2006) 0.89
Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients. PLoS One (2013) 0.89
High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users. J Med Virol (2007) 0.88
Selective transmission of hepatitis C virus quasi species through a needlestick accident in acute resolving hepatitis. Clin Infect Dis (2006) 0.88
Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis (2007) 0.87
Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Hepatology (2011) 0.87
The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. J Hepatol (2008) 0.87
Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan. J Med Virol (2003) 0.87
The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. Kidney Int (2010) 0.86
Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology (2007) 0.86
Metabolic profiles in patients with chronic hepatitis C: a case-control study. Hepatol Int (2008) 0.86
Naturally occurring hepatitis B surface gene variants in chronic hepatitis B virus infection: correlation with viral serotypes and clinical stages of liver disease. J Med Virol (2002) 0.86
Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. PLoS One (2012) 0.86
A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int (2015) 0.86
Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B. J Clin Gastroenterol (2015) 0.85